We will see an increasing number of digital aids for inhaler devices in the not too distant future. And no, I don’t know how much this costs, so I’ve dropped Novartis a line to find out more. The idea is that it both reminds the patient to take their meds and provides information about treatment adherence. Enerzair also comes with a ‘digital companion,’ a sensor that connects to an App, providing real-time data about inhaler use to both the patient and health professional. This was publicised as being the first ICS/LABA/LAMA (long-acting muscarinic antagonist) triple therapy for asthma 3 and is a much-welcomed addition to the fight to improve asthma control and reduce asthma deaths. But as well as supplying Atectura, they have launched another asthma therapy in the form of Enerzair Breezhaler. Novartis are more commonly known for marketing inhaled therapy for COPD. Personal feedback from COPD patients I have looked after who have used Ultibro Breezhaler has been very positive. Capsule inhalers may be a little on the old-fashioned side, but the Breezhaler requires a relatively low inspiratory flow rate compared to some DPIs, which may make it easier for some patients to inhale the powder out of the device. Atectura comes in the Breezhaler, which is a capsule Dry Powder Inhaler (DPI), which involves inserting the capsule in the device, squeezing a button to pierce the capsule, and then inhaling quickly and deeply 2. In this respect, you can think of it a little like Relvar, which is also a once-a-day fixed-dose combination. It also lasts 24 hours so is only taken once a day, which might be an advantage to help with adherence for some. However, it is available in three different strengths, which provides some flexibility in dosing, often an advantage in a variable condition such as asthma. Atectura is a fixed-dose combination, meaning that you can’t increase and decrease the dose, as you can with formoterol-based combinations such as Symbicort and Fostair. It contains the ICS mometasone, and the LABA indacaterol, which are perhaps less well known than others but still effective medicines. The good thing is that there are no extra devices for you to learn, just some extra combinations to provide another option for your people with Chronic Obstructive Pulmonary Disease (COPD) and asthma.Ītectura Breezhaler is a new inhaled corticosteroid (ICS) and long-acting B2 agonist (LABA) for asthma, marketed by Novartis. This time last year we were running out of inhalers, 1 and now we seem to be overrun by them. Triple ICS/LABA/LAMA FDC and dual LABA/LAMA or ICS/LABA FDCs are characterized by specific efficacy/safety profiles in agreement with the level of blood eosinophil count at baseline.ĬOPD ICS LABA LAMA dual bronchodilation network meta-analysis triple therapy.If you’re the kind of person who breaks out in a cold sweat every time you hear someone say “have you seen the latest inhaler that’s just come out,” then you may wish to pause a moment, light some scented candles, turn on some soothing music, and take a deep breath. The weighted efficacy/safety profile resulting from SUCRA provided the following ranking in patients with low eosinophil count: ICS/LABA/LAMA>LABA/LAMA≫ICS/LABA whereas in patients with high eosinophil count the ranking was as follows: ICS/LABA/LAMA>LABA/LAMA>ICS/LABA FDC. The treatment ranking was reported via the surface under the cumulative ranking curve analysis (SUCRA).ĭata obtained from 21,909 COPD patients were extracted from the ETHOS, KRONOS, IMPACT, and TRILOGY studies, the only that fulfilled the strict inclusion criteria of this research. either dual LABA/LAMA or ICS/LABA therapies administered at fixed-dose combination (FDC) via the same inhaler device.Ī network meta-analysis was performed to assess the efficacy/safety impact of triple ICS/LABA/LAMA FDC compared with dual LABA/LAMA and ICS/LBA FDCs administered via the same inhaler device in COPD patients. The aim of this study was a quantitative synthesis by considering the studies that directly compared triple ICS/LABA/LAMA vs. In some studies comparing triple with dual combination therapies in COPD there might be a possible effect of inhaler bias resulting from different inhaler devices being used in comparator arms.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |